Xellsmart, a stem-cell startup based in Suzhou, has reportedly raised over RMB 200 million (USD 27.6 million) in a Series A1 financing round. The round was co-led by Qiming Venture Partners, Lilly Asia Ventures, Xiamen Jinyuan Zhanhong Investment, and China-Singapore Suzhou Industrial Park Development Group. Other investors included Oriza Holdings, Founder H Fund, CE Innovation Capital, Frees Fund, Sequoia Capital China, and Next Capital. The proceeds will be used to fund a pre-clinical study for its iPS-derived cell therapy for neural system diseases, team expansion, and pilot production of its clinical-level iPS-derived cell therapies.
Company Profile and Pipeline
Founded in 2021, Xellsmart is focused on developing scaled-up, low-cost stem-cell therapies for major diseases, including Parkinson’s disease (PD). The company has completed the construction of an 1,800-square-meter R&D center and a large-scale manufacturing transformation plant. Xellsmart has also established key technology platforms, including iPS cell line reprogramming, iPSC gene editing, and differentiation of iPSCs into various subtypes of neural cells. Additionally, Xellsmart is a member of the CSDR’s cell and gene therapy product regulatory research committee.
Future Development Plans
The Series A1 funding will support Xellsmart’s pre-clinical study for its iPS-derived cell therapy, aimed at treating neural system diseases. The funds will also be used for team expansion and pilot production of its clinical-level therapies, positioning Xellsmart to advance its innovative treatments and improve accessibility for patients with neural diseases.-Fineline Info & Tech
